The disease burden of multimorbidity and its interaction with educational level

Yi Hsuan Chen, Milad Karimi, Maureen P. M. H. Rutten-van Möken

1 Erasmus School of Health Policy and Management, Erasmus University Rotterdam, Rotterdam, The Netherlands,
2 Institute for Medical Technology Assessment, Erasmus University Rotterdam, Rotterdam, The Netherlands

* These authors contributed equally to this work.
† Current address: Erasmus School of Health Policy and Management, Erasmus University Rotterdam, Rotterdam, The Netherlands
‡ Current address: Institute for Medical Technology Assessment, Erasmus University Rotterdam, Rotterdam, The Netherlands

Abstract

Introduction

Policies to adequately respond to the rise in multimorbidity have top-priority. To understand the actual burden of multimorbidity, this study aimed to: 1) estimate the trend in prevalence of multimorbidity in the Netherlands, 2) study the association between multimorbidity and physical and mental health outcomes and healthcare cost, and 3) investigate how the association between multimorbidity and health outcomes interacts with socio-economic status (SES).

Methods

Prevalence estimates were obtained from a nationally representative pharmacy database over 2007–2016. Impact on costs was estimated in a fixed effect regression model on claims data over 2009–2015. Data on physical and mental health and SES were obtained from the National Health Survey in 2017, in which the Katz-10 was used to measure limitations in activities of daily living (ADL) and the Mental Health Inventory (MHI) to measure mental health. SES was approximated by the level of education. Generalized linear models (2-part models for ADL) were used to analyze the health data. In all models an indicator variable for the presence or absence of multimorbidity was included or a categorical variable for the number of chronic conditions. Interactions terms of multimorbidity and educational level were added into the previously mentioned models.

Results

Over the past ten years, there was an increase of 1.6%-point in the percentage of people with multimorbidity. The percentage of people with three or more conditions increased with 2.1%-point. People with multimorbidity had considerably worse physical and mental health outcomes than people without multimorbidity. For the ADL, the impact of multimorbidity was
three times greater in the lowest educational level than in the highest educational level. For the MHI, the impact of multimorbidity was two times greater in the lowest than in the highest educational level. Each additional chronic condition was associated with a greater worsening in health outcomes. Similarly, for costs, where there was no evidence of a diminishing impact of additional conditions either. In patients with multimorbidity total healthcare costs were on average €874 higher than in patients with a single morbidity.

**Conclusion**

The impact of multimorbidity on health and costs seems to be greater in the sicker and lower educated population.

---

**Introduction**

Multimorbidity, defined as two or more chronic conditions occurring in one person at the same time, is an increasing problem, particularly in countries with a rapidly ageing population [1, 2]. The number of patients with multimorbidity in Europe is around 50 million and is increasing every year [2]. Compared to patients without multimorbidity, those with multimorbidity have a higher mortality rate [3, 4], a higher rate of polypharmacy [5], worse health-related quality of life (HRQoL) [6–8], higher healthcare costs [9–11], and more productivity loss [12] after adjustment of age and other confounders. Moreover, they are disproportionately affected by the fragmentation and the single-disease orientation of the health and social care system [13]. The need for investments in potential solutions such as whole-system, person-centred integrated care is widely recognized. To justify and plan such investments and ensure access for all people with multimorbidity across the layers of the population, it is crucial to have accurate data on the (change in) prevalence of multimorbidity and its impact on physical and mental health, and costs.

Prevalence estimates of multimorbidity and their increase with age and over time vary considerably due to differences in definitions of multimorbidity and sources of data used [14–18]. The most up to date prevalence estimate for the Netherlands was 31.8% in 2018 [19], which was based on a general practitioner (GP) registry. An estimate of (change in) prevalence that is based on a national database representing the entire Dutch population is lacking.

Several studies have investigated the association between multimorbidity and health outcomes, both physical [6–8, 20–22], and mental [6, 8, 23, 24], but many were either small [7, 21], not representative for the entire country [8, 23], focused on a specific subgroup like elderly [6, 7, 21, 22], or focused on a limited number of chronic diseases [24–26]. There are many papers on socio-economic inequalities in health, which clearly demonstrate that lower SES is associated with greater mortality [27, 28], higher prevalence of multimorbidity [29] and worse health outcomes [30] To the best of our knowledge, none of them investigated how the association between multimorbidity and health varies by SES.

The impact of multimorbidity on costs varies by healthcare system and methods used to derive costs [10, 31]. In a recent review study, the ratios of multimorbidity costs to non-multimorbidity costs ranged from 2–16 [32]. Most of the studies in this review were cross-sectional and half of them were based on U.S. data. There is no longitudinal study on the impact of multimorbidity on healthcare costs in the Netherlands.

The aim of our study was to fill in the information gaps identified above. This study provides recent estimates of the prevalence of multimorbidity in the Netherlands and its change.
over time. Furthermore, we investigated the association between multimorbidity and physical health, mental health and healthcare costs, using databases that are representative for the entire country. In addition, we investigated how educational level interacts with the association between multimorbidity and health.

Methods

We have used data from a nationally representative pharmacy database, claims database and a health survey to estimate the change in prevalence of multimorbidity and the impact of multimorbidity on health and healthcare costs. All databases used in this study were provided by Statistics Netherlands (CBS, Centraal Bureau voor de Statistiek), the national statistics office of the Netherlands. The study population was the entire adult population (18 years old and over) in the Netherlands. The prevalence estimation was based on data from 2006 to 2016, the association between multimorbidity and health outcomes was based on data from 2017, and the estimated impact of multimorbidity on healthcare costs was based on panel data from 2009 to 2015.

Identification of chronic conditions and prevalence of multimorbidity

To estimate the prevalence, we used a longitudinal pharmacy database that contained data from everyone in the Netherlands that received medication included in the basic health insurance package, which is approximately 11 million adults (85% of total population) each year [33]. In the Netherlands, every resident is mandatorily enrolled in basic health insurance. All prescribed medicines covered by the basic insurance, including those prescribed by GP’s, to hospital outpatients and patients in residential homes, are recorded in this dataset. The medication prescribed during in-patient hospital stays and over-the-counter medicines are not included in the pharmacy database.

The individual-level prescriptions of medications are coded and categorized using the Anatomical Therapeutic Chemical (ATC) classification system, up to the third level, which is the pharmacological subgroup level [34]. We matched these ATC codes to a list of 21 chronic conditions: acid-related disorders, bone diseases, cancer, cardiovascular diseases, dementia, diabetes mellitus, epilepsy, glaucoma, hyperuricemia (gout), chronic viral infection, hyperlipidemia, intestinal inflammatory diseases, iron deficiency anemia, migraines, pain, Parkinson’s disease, psychological disorders, psychoses, respiratory illness, thyroid disorders, and tuberculosis. To do so we used the Swiss classification by Huber et al. [35], which was an updated version of the original Dutch classification by Lamers et al. [36], that was used in the risk equalization scheme of the Dutch health insurance. Hence this classification was deemed suitable to be used in a study addressing the entire adult population in the Netherlands.

In line with the WHO definition of multimorbidity, adults with two or more chronic conditions in the same year were defined as having multimorbidity [37]. To avoid overestimating the prevalence of chronic conditions, we only labeled a condition as chronic when medication for a certain chronic disease was prescribed at least two years in a row. This continuity criterion was used by previous studies [38, 39].

To estimate the prevalence of multimorbidity by gender and age, the pharmacy database was linked to the municipal basic administration (GBA, Gemeentelijke Basis Administratie) database from CBS, which contains demographic information (year of birth and gender) for all residents in the Netherlands [40]. Data were linked by CBS, using a pseudonymized common ID that is unique for each individual. Information on annual size of the total population in the Netherlands was extracted from StatLine [41].
Health outcomes

To estimate the association between multimorbidity and health outcomes, which include physical and mental health outcomes, we used data from the Health Survey database [42]. This database contains data from a nation-wide, cross-sectional, annual Health Survey on health and the need for healthcare in the Netherlands, including self-reported physical and mental health, and demographic information such as age, gender, and highest education level.

Approximately 15,000 participants across the country are sampled for the survey each year, with a response rate of 63% in 2017 (approximately 9,500 respondents), from which we selected all 7,741 respondents that were 18 years and older in the year 2017. The average age of this dataset is 52.8 years old, 50.5% of the respondents are male (S3 Table). The sample is distributed evenly over all months of the year. First, persons are asked to participate via the internet. Non-responders are re-approached to participate in a face-to-face interview by way of Computer-Assisted Personal Interviewing. A correction is applied to control for differences between the sample and the population. For this purpose, a weighting factor is used based on sex, age, migration background, marital status, degree of urbanisation, province, household size, income, wealth, and survey season. The background characteristics of the Health Survey responders were proven by CBS to be similar to the general population in the Netherlands [42].

Physical health was measured with the Katz-10. This is a validated questionnaire [43, 44], which consists of ten questions asking respondents whether they need help with ADL such as eating, dressing, personal hygiene, mobility in getting up from bed, dressing, transferring, and use of the toilet [45]. The five response options ranged from no difficulty to not even with the help of others. Participants under 54 years only had to answer three of these ten questions, i.e., about their ability to get up from a chair, to get up from a bed and walk up a flight of stairs. For both age groups, responses were linearly transformed onto a scale from 0 (best) to 100 (worst) [46].

Mental health was measured by the Mental Health Inventory 5 (MHI-5). This is a validated questionnaire [47], which consists of five questions asking how much of the time during the last four weeks the respondents had felt happy, calm and peaceful, nervous, downhearted and blue, and so down in the dumps that nothing could cheer them up [48]. The six response options ranged from none of the time to all of the time. Responses were linearly transformed onto a scale from 0 (worst) to 100 (best) [49].

The Health Survey database also contains age, gender, and highest education level achieved, which was classified into five levels, i.e. primary education; pre-vocational training; high school or vocational training; higher education until Bachelor; and master/doctorate [50]. The multimorbidity status of the Health Survey respondents was obtained by linking to the prevalence data (2016). In all the databases provided by CBS, each individual has one unique, encrypted RIN code. This RIN code enable us to link several databases on individual level.

Healthcare costs

To estimate the impact of multimorbidity on healthcare expenditure, we used a database of health insurance data, containing annual individual-level claims data from 2009 to 2015 [51]. Sixteen categories of costs are included, that cover all expenditures reimbursed by the compulsory basic health insurance in the Netherlands, including GP care, hospital care, dental care, pharmaceuticals, other costs (e.g. paramedic, assistive device and birth care), and total costs. Costs of GP care include the annual per capita registration fee, the consultation fees and other costs incurred by the GP. Costs of hospital care include both inpatient and outpatient hospital care. Pharmacy costs include all the costs of medicines, except for the ones administered
during a hospital admission. From the health insurance database, we included only the adult population (18 or older), which was around 2,450,000 each year in the period from 2009 to 2015 (17,048,049 observations for adults across these years in total).

As healthcare costs increase substantially in the year of death [52, 53], it was essential to have mortality data to know whether an individual had died in a certain year. Mortality data for all deceased Dutch residents were obtained from the National Mortality Database, which includes the date and cause of death of all residents in the Netherlands. End-of-life costs were defined as the healthcare expenditures during the year of death.

**Statistical analyses**

**Prevalence.** For each year from 2007 to 2016, the prevalence of multimorbidity was calculated as the number of adults with multimorbidity (in a certain age class) divided by the number of adults (in that age class) living in the Netherlands that year. We further classified patients according to their number of chronic conditions (0, 1, 2, 3, 4, and 5 or more) and estimated the prevalence of each class.

**Health outcomes.** To analyse the association between multimorbidity and ADL, we estimated two-part models (2PM), because a large proportion of the people has a score of 0, indicating no problems with their ADL [45]. This makes the conventional ordinary least squares (OLS) inappropriate. In the first part of the 2PM, we used a logit model to estimate the probability of having an ADL score higher than 0, including morbidity status (0 for no morbidity, 1 for single morbidity, and 2 for multimorbidity), age, gender and educational level:

\[
P_r(ADL_i > 0 | X_i) = \frac{e^{\alpha + \beta \cdot x_i}}{1 + e^{\alpha + \beta \cdot x_i}}
\]

Where \( P_r(ADL_i > 0 | X_i) \) is the probability of ADL score to be positive with given age, gender, multimorbidity status, and education level, \( \alpha \) is the constant, and \( \beta \) are parameters in the model, which are age, gender, multimorbidity status and education level.

The second part of the 2PM estimated the ADL score among those with a non-zero score, using a generalized linear model with a gamma distribution and log-link function, because the data were skewed to the right. The choice of the model was driven by the Manning and Mullahy algorithm [54]. Like in the first part, the model included morbidity status, age, gender and educational level:

\[
\ln(E(ADL_i)) = \alpha + \beta \cdot x_i + \varepsilon
\]

Where \( \varepsilon \) stands for the error term. The results of the 2PM combined the probability estimated in the first part and the ADL score estimated in the second part:

\[
E(ADL_i | x_i) = P_r(ADL_i > 0 | X_i) \cdot E(ADL_i | x_i, \ ADL_i > 0)
\]

To analyse the association between multimorbidity and MHI score, we estimated a generalized linear model with the same independent variables as above. Based on the Manning and Mullahy algorithm [54], the identity link function and normal distribution were chosen in this analysis:

\[
MHI_i = \alpha + \beta \cdot x_i + \varepsilon
\]

To investigate whether the association between multimorbidity and ADL or MHI scores differed by level of education, interaction variables of morbidity status and level of education were added to the models above.
Healthcare costs. We used fixed-effects regression models to estimate the associations between multimorbidity and healthcare costs [55]. A major concern for observational studies involving human behaviours is the presence of unmeasured potential confounding factors. With the panel dataset that provided individual-level information, we addressed this concern by the ‘within estimation’ of a fixed-effect model, which takes each individual as its own control and estimates the change in healthcare costs of each individual after the morbidity status changed and cancels out those unmeasured, time-invariant confounding factors such as medical care-seeking behaviour [55].

In all models the three-level morbidity status (i.e., 0, 1 for single morbidity, 2 for multimorbidity (i.e., ≥2)) was replaced by a six-level morbidity status (i.e., 0, 1, 2, 3, 4, and 5 or more) to investigate the impact of the number of morbidities on health outcomes and costs. All analyses were conducted using Stata 14 statistical software.

Results

Prevalence

The prevalence of multimorbidity in Dutch adults was 23.2% in 2007 and had increased to 24.7% in 2016 (S1 Table). This raise was primarily due to an increase in those aged over 69 (Fig 1). Compared to 2007, the prevalence has risen with 1.5% points. Over the past ten years, there was a considerable increase in the proportion of people with three or more chronic conditions (Fig 2).

![Fig 1. Change in prevalence or multimorbidity by age groups compared to 2007.](https://doi.org/10.1371/journal.pone.0243275.g001)
According to the prevalence estimations in 2016, the prevalence of multimorbidity increased sharply with age to 76.2% in the 80 years old or older.

**Health outcomes**

Table 1 shows the association between multimorbidity and health outcomes, both for physical and mental health. The odds ratio of having a non-zero ADL score (i.e. having ADL problems) was 3.8 (13.17/3.43) times higher for the multimorbidity group than for the single morbidity group, after adjustment for differences in age, gender, and education level (Table 1). Among those with a non-zero ADL score, the ADL score of those with multimorbidity was 2.2 (1.2*10.6–1.4*10.6) units worse than the ADL score of those with a single morbidity. Combining the results of both parts, the ADL score of the multimorbidity group was 3 units worse than the ADL score of the single morbidity group. Table 1 also shows that, compared to the non-morbidity group, the MHI score worsened by 1.7 units in the single morbidity group and 5 units in the multimorbidity group.

The regression results showing the association between multimorbidity and physical and mental health outcomes across different education levels are reported in S2 Table. Fig 3 shows the interaction between educational level and the impact of multimorbidity on ADL, and Fig 4 does so for the MHI. The lower the education level, the greater the difference in ADL score and MHI score between multimorbidity and no morbidity. Compared to the non-morbidity group.
group, the ADL score was 6.6 units worse in the group with the lowest educational level, whereas it was only 2.3 units worse in the group with the highest educational level. Compared to the non-morbidity group, the MHI score was 6.4 units worse in the group with the lowest educational level, whereas it was only 3.5 units worse in the group with the highest educational level.

Table 2 shows the association between the number of chronic conditions and the ADL and MHI scores. The group with two chronic conditions had an ADL score that was 1.7 units (calculated with Eq (3)) worse than the group with no chronic conditions, whereas the group with five or more chronic conditions had an ADL score that was 10 units (calculated with Eq (3)) worse. The MHI score for the group with two chronic conditions was 3.4 units worse than that of the group with no chronic conditions, whereas that of the group with five or more chronic conditions was 8.7 units worse.

As the number of chronic conditions increased, the difference in ADL score between two consecutive groups increased as well; i.e., the difference between the group with one chronic condition and the group with two chronic conditions was 0.8 units, whereas the difference between the group with three chronic conditions and the group with four chronic conditions was almost two units (Table 2). The same picture was seen for the MHI.

Healthcare costs

Table 3 shows the association between multimorbidity and healthcare costs. Costs are presented in Euros (2015 exchange rate: 1$US = 0.92 €). Compared with those in the single-morbidity group, the mean total health costs of the multimorbidity group was € 874 higher. The
costs of GP care, pharmaceuticals, and hospital care were €25, €226, and €355 higher in multimorbidity patients than in single-morbidity patients.

Table 4 shows the impact of the number of chronic conditions on total healthcare costs. One chronic condition increased the annual costs with €600 whereas five or more conditions increased the costs with €3,949. Proportionally similar increases were seen for the categories of costs.

**Discussion**

Our results demonstrated that multimorbidity has not only become more prevalent (0.4 million additional people with multimorbidity) but also more severe in the Netherlands over the past ten years. The percentage of people with three or more conditions increased and this increase was highest in the category with five or more chronic conditions (0.8%-point). Hence, the people with multimorbidity have more chronic conditions with increases their complexity and further increases the challenges to the provision of integrated chronic care.

Compared with the latest reported Dutch study, our study showed a higher prevalence of multimorbidity but a slower rate of increase over time. This previous study reported a prevalence estimate of 16.2% in 2011 [17], while our estimate was 24.4% in the same year. Prevalence estimates may vary as a result of a difference in population studied, list of chronic

---

Fig 3. Difference in ADL score compared to no morbidity across education levels. The number of participants is 7,741. The group without a chronic condition is the reference group. *: A higher score indicates a worse ADL. The standard error bars were based on bootstrapping. **: Education level: 1 for primary school; 2 for Pre-vocational training; 3 for High school or vocational training; 4 for Higher education until Bachelor; 5 for Master/doctorate.

https://doi.org/10.1371/journal.pone.0243275.g003
conditions used, and source of data [56]. In contrast to our study, which was based on pharmacy data, this previous study was based on regional GP-registrations. It reported an increase in prevalence of multimorbidity of 0.4%-point per year, whereas our estimate showed 0.15%-point increase per year. Our estimate might be lower because we estimated the increase on the general population instead of regional GP-registrations.

Our study further showed that multimorbidity was associated with impaired physical and mental health. More importantly, for each additional chronic condition the additional impairment increased. The negative association between multimorbidity and physical health is in line with previous studies [20, 57, 58], among which two studies based on Dutch data [6, 7]. However, these Dutch studies included people of 85 years or over who already have a worse ADL score due to ageing alone. The negative association between multimorbidity and mental health is also in line with previous studies [23, 24], although Fortin et al. reported a weaker association [23]. The increasing impairment from each additional chronic disease further stresses the need to adopt a person-centred holistic approach instead of a disease-specific approach towards chronic disease management.

Our study clearly showed that multimorbidity disproportionally affected people with a lower education level. The negative impact of multimorbidity on ADL was about three times greater in those with the lowest education level than in those with the highest education level. The negative impact of mental health was about two times greater, respectively. We found no previous studies comparing the impact of multimorbidity between groups with different education levels. This result highlights the need to specifically engage the lower educated patients...
in chronic disease management and provide targeted self-management support to the lower educated patients.

Multimorbidity increased the total healthcare cost by €874 as compared to people with a single chronic condition. This was largely due to an increase in costs of medication (+€355).

Table 2. Associations between chronic conditions and health outcomes (N = 7,741).

| Health outcome | ADL | MHI |
|----------------|-----|-----|
| Model          | Part 1: Logistic | Part 2: GLM | OLS |
|                | OR** | 95% CI | Exp(b**) | 95% CI | b** | 95% CI |
| Age            | 1.02 | 1.02 | 1.03 | 0.99 | 0.98 | 0.99 | 0.10 | 0.09 | 0.12 |
| Female         | 1.36 | 1.19 | 1.55 | 1.15 | 1.05 | 1.26 | -1.59 | -1.94 | -1.24 |

Education level* (reference: 1)

|          | 2 | 0.76 | 0.61 | 0.95 | 0.77 | 0.67 | 0.89 | 0.54 | -0.07 | 1.16 |
|          | 3 | 0.69 | 0.56 | 0.84 | 0.68 | 0.59 | 0.78 | 1.48 | 0.92 | 2.05 |
|          | 4 | 0.63 | 0.49 | 0.80 | 0.63 | 0.53 | 0.75 | 2.02 | 1.39 | 2.66 |
|          | 5 | 0.42 | 0.31 | 0.58 | 0.68 | 0.54 | 0.87 | 1.88 | 1.13 | 2.62 |

Number of chronic conditions (reference: no chronic condition)

|          | 1 | 3.53 | 2.75 | 4.53 | 1.18 | 0.95 | 1.48 | -1.79 | -2.26 | -1.32 |
|          | 2 | 6.87 | 8.80 | 8.80 | 1.11 | 0.89 | 1.39 | -3.41 | -3.96 | -2.86 |
|          | 3 | 11.03 | 14.33 | 14.33 | 1.12 | 0.94 | 1.47 | -4.41 | -5.07 | -3.75 |
|          | 4 | 18.35 | 24.06 | 24.06 | 1.40 | 1.12 | 1.75 | -5.88 | -6.61 | -5.14 |
|          | 5 or more | 47.10 | 61.97 | 61.97 | 1.91 | 1.55 | 2.37 | -8.65 | -9.35 | -7.96 |
| Constant  | 0.05 | 0.06 | 0.06 | 10.54 | 8.51 | 13.04 | 5.89 | 5.84 | 5.95 |

The number of participants is 7,741. The part 1 model of ADL is calculated with Eq (1); the part 2 model of ADL is calculated with Eq (2); the model of MHI is calculated with Eq (4).

*Education level: 1 for primary school; 2 for Pre-vocational training; 3 for High school or vocational training; 4 for Higher education until Bachelor; 5 for Master/doctorate.

**OR: odds ratio, b: regression-coefficient

https://doi.org/10.1371/journal.pone.0243275.t002

Table 3. Associations between multimorbidity and healthcare costs (in Euro).

| Cost types        | Total cost | GP cost | Pharmacy cost | Hospital care cost |
|-------------------|------------|---------|---------------|--------------------|
|                   | b** | 95% CI | b** | 95% CI | b** | 95% CI | b** | 95% CI |
| Morbidity condition (reference: no chronic condition) |
| Single morbidity  | 613.0 | 607.7 | 618.4 | 21.8 | 21.7 | 21.9 | 140.3 | 139.6 | 141.1 | 316.0 | 312.1 | 320.0 |
| Multimorbidity    | 1,487.0 | 1,479.9 | 1,494.2 | 47.4 | 47.2 | 47.5 | 365.9 | 364.9 | 366.9 | 661.3 | 656.0 | 666.6 |
| Death*            | 3,685.0 | 3,670.3 | 3,699.7 | 199.0 | 198.8 | 199.3 | -266.8 | -269.0 | -264.7 | 2,998.0 | 2,987.2 | 3,008.9 |
| Year (reference: 2009) |
| 2010              | 119.0 | 115.0 | 123.1 | 2.2 | 2.1 | 2.2 | 15.5 | 14.9 | 16.1 | 65.3 | 62.3 | 68.3 |
| 2011              | 236.7 | 232.6 | 240.7 | 15.9 | 15.8 | 15.9 | 26.2 | 25.7 | 26.8 | 140.8 | 137.8 | 143.7 |
| 2012              | 299.5 | 295.5 | 303.6 | 15.3 | 15.2 | 15.3 | 6.8 | 6.3 | 7.4 | 239.4 | 236.4 | 242.4 |
| 2013              | 513.9 | 509.8 | 517.9 | 22.4 | 22.3 | 22.4 | 6.1 | 5.5 | 6.7 | 351.3 | 348.3 | 354.3 |
| 2014              | 584.8 | 580.7 | 588.9 | 34.8 | 34.8 | 34.9 | 15.2 | 14.6 | 15.8 | 396.8 | 393.8 | 399.8 |
| 2015              | 729.4 | 725.3 | 733.5 | 37.2 | 37.1 | 37.3 | 31.3 | 30.7 | 31.9 | 372.1 | 369.1 | 375.2 |
| Constant          | 1,303.9 | 1,300.6 | 1,307.3 | 101.9 | 101.9 | 102.0 | 169.3 | 168.8 | 169.8 | 707.2 | 704.7 | 709.7 |

*Death: 1 if the individual died in the given year; 0 if the person did not die in the given year

**b: coefficient

https://doi.org/10.1371/journal.pone.0243275.t003
and costs of hospital care (+€226). There is no evidence of diminishing increases as the number of conditions increases. The association between multimorbidity and costs was previously reported for Switzerland, Ireland, and the U.S. [32], and although they all found considerable increases, the absolute increases are difficult to compare because of difference in healthcare and insurance systems, prices, medical practice patterns and databases used. Previous Dutch studies [59, 60] have only reported the association between multimorbidity and healthcare utilization, but not costs.

Strength and limitations

A strength of our study was the use of comprehensive databases, yielding representative results for the Netherlands. The Health Survey that was used to measure physical and mental health, is send to a random sample of the Dutch adult population, and bias due to non-response is reduced by weighting the data with respect to sex, age, ethnicity, marital status, geographic characteristics, and survey season [61]. The pharmacy database that we used to estimate the prevalence of multimorbidity covered over 90% of the population in the Netherlands. This pharmacy database includes all medication prescribed by GP’s, to hospital outpatients and patients in residential homes, but not medication prescribed during a hospital admission and the over-the-counter medication. However, it is unlikely that this limitation has affected the prevalence of multimorbidity because most chronic conditions require continuous pharmacotherapy with medicines that are only available on prescription from doctors and these prescriptions are generally filled at local outpatient pharmacies. The health insurance database we used included 98% of all declarations for services included in the basic benefit package. However, services covered by private health insurance and out-of-pocket expenditures were not included. In 2015, they amounted to about 4.4% and 14.2% of total healthcare costs, respectively [62]. Out-of-pocket payments mostly included the deductible of the basic health

### Table 4. Associations between the number of chronic conditions and healthcare costs (in Euro).

| Cost types | Total cost | GP cost | Pharmacy cost | Hospital care cost |
|------------|------------|---------|---------------|--------------------|
|            | b** | 95% CI  | b** | 95% CI  | b** | 95% CI  | b** | 95% CI  |
| Number of chronic conditions (reference: no chronic condition) |       |         |       |         |       |         |       |         |
| 1          | 600.6      | 595.3   | 606.0   | 21.5  | 21.4   | 21.5  | 137.2  | 136.4  | 137.9  | 311.5  | 307.6  | 315.5  |
| 2          | 1,202.5    | 1,195.0 | 1,210.0 | 39.3  | 39.2   | 39.5  | 291.7  | 290.6  | 292.8  | 559.3  | 553.8  | 564.8  |
| 3          | 1,869.9    | 1,860.4 | 1,879.3 | 58.7  | 58.6   | 58.9  | 470.1  | 468.7  | 471.5  | 792.9  | 785.9  | 799.9  |
| 4          | 2,701.0    | 2,689.1 | 2,713.0 | 80.5  | 80.3   | 80.7  | 675.9  | 674.2  | 677.7  | 1,110.7 | 1,101.9 | 1,119.6 |
| 5 or more  | 3,949.3    | 3,934.3 | 3,964.4 | 114.2 | 114.0  | 114.4 | 987.2  | 985.1  | 989.4  | 1,558.4 | 1,547.2 | 1,569.5 |
| Death*     | 3,656.8    | 3,642.1 | 3,671.5 | 198.3 | 198.0  | 198.5 | -273.9 | -276.0 | -271.7 | 2,987.7 | 2,976.8 | 2,998.5 |

Year (reference: 2009)

|         | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | Constant |
|---------|------|------|------|------|------|------|-----------|
| 2010    | 108.4 | 104.4 | 112.4 | 1.9 | 1.8 | 2.0 | 12.8 | 12.2 | 13.4 | 61.4 | 58.5 | 64.4 |
| 2011    | 212.5 | 208.4 | 216.5 | 15.2 | 15.1 | 15.3 | 20.1 | 19.5 | 20.7 | 131.9 | 129.0 | 134.9 |
| 2012    | 268.0 | 264.0 | 272.1 | 14.4 | 14.4 | 14.5 | -1.2 | -1.8 | -0.6 | 227.9 | 224.9 | 230.9 |
| 2013    | 478.8 | 474.7 | 482.9 | 21.4 | 21.3 | 21.5 | -2.9 | -3.4 | -2.3 | 338.6 | 335.6 | 341.6 |
| 2014    | 541.3 | 537.2 | 545.3 | 33.7 | 33.6 | 33.7 | 4.1 | 3.5 | 4.7 | 381.0 | 377.9 | 384.0 |
| 2015    | 676.4 | 672.3 | 680.5 | 35.7 | 35.7 | 35.8 | 17.8 | 17.2 | 1.8 | 352.9 | 349.8 | 355.9 |
| Constant | 1,244.6 | 1,241.2 | 1,247.9 | 100.3 | 100.2 | 100.3 | 154.1 | 153.6 | 154.6 | 685.6 | 683.2 | 688.1 |

*Death: 1 if the person died in that given year; 0 if the person did not die in the given year

**b**: coefficient

[https://doi.org/10.1371/journal.pone.0243275.t004](https://doi.org/10.1371/journal.pone.0243275.t004)
insurance (max €375 per person in 2015) and certain services like eyeglasses, contact lenses, inlay soles and certain dental prostheses that not covered by basic health insurance. The latter is generally not caused by or unique to certain chronic diseases. The deductible (the amount paid out of pocket by the patient before a health insurer will pay any expenses) can be substantial for patients with chronic diseases, but was not included because we only had data on costs covered by the basic health insurance.

While many chronic conditions can be identified well based on pharmacy data, some are more difficult. For example, a condition like chronic pain is challenging to identify since pain-controlling medications are also accessible as over-the-counter medication, which is not recorded in the pharmacy database. However, the stronger pain-controlling medications, such as morphine, fentanyl and oxycodone, are only accessible with specialists’ prescription, which are included on the pharmacy data. Additionally, the possibility of overestimating the prevalence of multimorbidity was reduced by applying the two-year continuously prescription criteria in defining chronic conditions. However, the prescription of preventive medication at the subclinical stage could lead to an overestimation. This especially pertains to hypertension-control. To investigate the potential influence on the results, a sensitivity analysis that excluded the first-line medications for hypertension-control (i.e. ATC code of diuretic agents) was performed. This analysis shows a similar result. The prevalence of multimorbidity is 1.5 to 2%-point lower than the original results and has a similar incremental trend.

A limitation of our study is that the Health Survey database only includes cross-sectional data [42]. Consequently, the analysis of these data precluded conclusions on the causal association between multimorbidity and physical and mental health outcomes [63]. On the other hand, the impact of multimorbidity on the healthcare cost was estimated in panel data, which does allow conclusions about causality since the unmeasured confounding factors and reversed causality can be better addressed with panel data [64].

The possible non-response bias is inevitable for most questionnaire-based studies, and there is no exception for the Health Survey database used in this study. However, this bias is addressed by a weighting that CBS applies to ensure representation by age, gender, marital status, province, household size, income and urbanity [61].

A further limitation is that we had to use ADL score as a proxy for physical health. The questions in the ADL questionnaire are more applicable to people who are more severely ill, which limits the assessment of subtle influences of chronic conditions on physical functioning [65]. In future surveys a more comprehensive measure of physical health should be used.

Additionally, for future studies it would be interesting to analyse disease clusters to have more insight in the effect of certain diseases combinations. That would, however, require a larger sample size than in our current study.

**Implications**

The implications of these findings are that they raise awareness of the increasing problem of multimorbidity, which calls for greater efforts in trying to limit the impact thereof on persons’ lives. These efforts should specifically target the more vulnerable groups such as those with a lower education level. Person-centred integrated health and social care initiatives are expected to contribute to the solution. However, surprisingly few of them offer additional or specific services and support for lower educated groups. While recognizing it won’t be easy to reach these groups, there is definitely a window of opportunity there. However, when more attention is being paid to integrated care for people with a lower education level, the risk of stigmatizing this group increases. Although there is an association between lower education level and worse health, the majority of the population, also from the lower educated groups, is healthy. This
calls for carefully targeting interventions to people within the lower educated group that need support most.

**Conclusion**

This analysis of nationally representative data from the Netherlands has shown that multimorbidity is associated with seriously impaired physical and mental health and disproportionately affects those with a lower education level. The impact of each additional chronic condition seems to grow as the number of chronic conditions increases. Each additional chronic condition leads to a considerable increase in costs, especially for medication and hospital costs, and there is no evidence of diminishing impact as the number of chronic conditions increases.

**Supporting information**

S1 Table. Prevalence of chronic diseases and multimorbidity from 2007 to 2016. (DOCX)

S2 Table. Associations between multimorbidity and health outcomes across education levels. (DOCX)

S3 Table. The demographic summary for the Health Survey database. (DOCX)

S1 Appendix. Stata code for statistical analyses. (DOCX)

**Acknowledgments**

Special thanks to Dr. Looman and Dr. Kuppen for their contributions to the method of identifying chronic conditions.

**Author Contributions**

**Conceptualization:** Yi Hsuan Chen, Milad Karimi, Maureen P. M. H. Rutten-van Mölken.

**Formal analysis:** Yi Hsuan Chen.

**Methodology:** Yi Hsuan Chen, Milad Karimi, Maureen P. M. H. Rutten-van Mölken.

**Software:** Yi Hsuan Chen.

**Supervision:** Milad Karimi, Maureen P. M. H. Rutten-van Mölken.

**Writing – original draft:** Yi Hsuan Chen.

**Writing – review & editing:** Milad Karimi, Maureen P. M. H. Rutten-van Mölken.

**References**

1. Afshar S, Roderick PJ, Kowal P, Dimitrov BD, Hill AG. Multimorbidity and the inequalities of global ageing: a cross-sectional study of 28 countries using the World Health Surveys. BMC public health. 2015; 15: 776. https://doi.org/10.1186/s12889-015-2008-7

2. Rijken M, Struckmann V, Dyakova M, Gabriella Melchiorre M, Rissanen S, van Ginneken E. ICARE-E4EU: improving care for people with multiple chronic conditions in Europe. Eurohealth. 2013; 19 (3):29–31.
3. Rizzuto D, Melis RJF, Angleman S, Qiu C, Marengoni A. Effect of Chronic Diseases and Multimorbidity on Survival and Functioning in Elderly Adults. Journal of the American Geriatrics Society. 2017; 65: 1056–1060. https://doi.org/10.111/jgs.14868

4. Nunes Bruno Pereira|Flores Thaynã Ramos|Mielke Grégore Ivan|Thumé Elaine|Facchini Luiz Augusto. Multimorbidity and mortality in older adults: a systematic review and meta-analysis. Archives of Gerontology and Geriatrics. 2016; 67: 130–138. https://doi.org/10.1016/j.archger.2016.07.008

5. Calderón-Larrañaída A, Poblador-Plou B, González-Rubio F, Gimeno-Feliú LA, Abad-Diez JM, Prados-Torres A. Multimorbidity, polypharmacy, referrals, and adverse drug events: are we doing things well? The British journal of general practice: the journal of the Royal College of General Practitioners. 2012; 62: e621–e626. https://doi.org/10.3399/bjgp12X659295

6. Drewes Yvonne M, den Elzen Wendy P J, Mooijaart Simon P, de Craen Anton J M, Assendelft Willem J J, Gussekloko Jacobijn. The effect of cognitive impairment on the predictive value of multimorbidity for the increase in disability in the oldest old: the Leiden 85-plus Study. Age and Ageing. 2011; 40: 352–357. https://doi.org/10.1093/ageing/af010

7. Laan Wijnand|Bleijenberg Nienke|Drubbel Irene|Numans Mattijs E.|de Wit Niek J.|Schuurmans Marieke J. Factors associated with increasing functional decline in multimorbidity independently living older people. Maturitas. 2013; 75: 276–281. https://doi.org/10.1016/j.maturitas.2013.04.005

8. Aarts Silvan den Akker Marjan|Bosma Hans|Tan Frans|Verheij Frans|Metsemakers Job, et al. The effect of multimorbidity on health related functioning: Temporary or persistent? Results from a longitudinal cohort study. Journal of Psychosomatic Research. 2012; 73: 211–217. https://doi.org/10.1016/j.jpsychores.2012.05.014

9. Bährler C, Huber CA, Brünger B, Reich O. Multimorbidity, health care utilization and costs in an elderly community-dwelling population: a claims data based observational study. BMC health services research. 2015; 15: 23. https://doi.org/10.1186/s12913-015-0698-2

10. Glynn LG, Valderas JM, Healy P, Burke E, Newell J, Gillespie P, et al. The prevalence of multimorbidity in primary care and its effect on health care utilization and cost. Family Practice. 2011; 28: 516–523. https://doi.org/10.1093/fampra/cm013

11. Skinner HG, Coffey R, Jones J, Heslin KC, Moy E. The effects of multiple chronic conditions on hospitalization costs and utilization for ambulatory care sensitive conditions in the United States: a nationally representative cross-sectional study. BMC health services research. 2016; 16: 77. https://doi.org/10.1186/s12913-016-1304-y

12. Ubalde López M, Arends I, Almansa J, Delclos GL, Gimeno D, Bültmann U. Beyond Return to Work: The Effect of Multimorbidity on Work Functioning Trajectories After Sick Leave due to Common Mental Disorders. Journal of Occupational Rehabilitation. 2017; 27: 210–217. https://doi.org/10.1007/s10926-016-9647-0

13. Sinnott C, Mc Hugh S, Browne J, Bradley C. GPs’ perspectives on the management of patients with multimorbidity: systematic review and synthesis of qualitative research. BMJ Open. 2013; 3: e003610. https://doi.org/10.1136/bmjopen-2013-003610

14. Barnett K, Mercer SW, Norbury M, Watt G, Wyke S, Guthrie B. Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study. The Lancet. 2012; 380: 37–43. https://doi.org/10.1016/S0140-6736(12)60240-2

15. Agborsangaya CB, Lau D, Lahtinen M, Cooke T, Johnson JA. Multimorbidity prevalence and patterns across socioeconomic determinants: a cross-sectional survey. BMC public health. 2012; 12: 201. https://doi.org/10.1186/1471-2458-12-201

16. Pache B, Vollenweider P, Waeger B, Marques-Vidal P. Prevalence of measured and reported multimorbidity in a representative sample of the Swiss population. BMC Public Health. 2015; 15: 164. https://doi.org/10.1186/s12889-015-15-x

17. van Oostrom Sandra H, Gispen Ronald, Stibru Irina, Korevaar Jake C, Schellevis Francois G, Picavet H Susan J, et al. Time Trends in Prevalence of Chronic Diseases and Multimorbidity Not Only due to Aging: Data from General Practices and Health Surveys. PLoS One. 2016; 11: e0160264. https://doi.org/10.1371/journal.pone.0160264

18. Uijen AA, van de Lisdonk Eloy H. Multimorbidity in primary care: Prevalence and trend over the last 20 years. European Journal of General Practice. 2008; 14: 28–32. https://doi.org/10.1080/13814780802436093

19. M.M.J. Nielen, M.J.J.C. Poos, A.M. Gommer, red. Volksgezondheidenzorg.org. 2019. https://www.volksgezondheidenzorg.org/onderwerp/chronische-ziekten-en-multimorfibiditeit/cijfers-context/huidige-situatie#node-preventie-multimorfibiditeit-naar-aantal-chronische-aandoeningen.

20. Arokiasamy P, Uttamacharya U, Jain K, Biritwum RB, Yawson AE, Wu F, et al. The impact of multimorbidity on adult physical and mental health in low- and middle-income countries: what does the study on
21. Boeckxstaens P, Vaes B, Legrand D, Dalleur O, Sutter AD, Degryse J. The relationship of multimorbidity with disability and frailty in the oldest patients: A cross-sectional analysis of three measures of multimorbidity in the BELFRAIL cohort. European Journal of General Practice. 2015; 21: 39–44. https://doi.org/10.3109/13814788.2014.914167

22. Park B, Ock M, Lee HA, Lee S, Han H, Jo M, et al. Multimorbidity and health-related quality of life in Koreans aged 50 or older using KNHANES 2013–2014. Health Qual Life Outcomes. 2018; 16: 1–10. https://doi.org/10.1186/s12955-018-1016-6

23. Fortin Martin, Bravo Gina, Hudon Catherine, Lapointe Lise, Almirall José, Dubois Marie-France, et al. Relationship between Multimorbidity and Health-Related Quality of Life of Patients in Primary Care. Qual Life Res. 2006; 15: 83–91. https://doi.org/10.1007/s11136-005-8661-z

24. van der Zee-Neuven A, Putrik P, Ramiro S, Keszei A, de Bie RA, Chorus A, et al. Impact of Chronic Diseases and Multimorbidity on Health and Health Care Costs: The Additional Role of Musculoskeletal Disorders. Arthritis Care & Research. 2016; 68: 1823–1831. https://doi.org/10.1002/acr.22913

25. Arokiasamy P, Uttamacharya U, Jain K, Birithwum RB, Yawson AE, Wu F, et al. The impact of multimorbidity on adult physical and mental health in low- and middle-income countries: what does the study on global ageing and adult health (SAGE) reveal? BMC Medicine. 2015; 13. https://doi.org/10.1186/s12916-015-0402-8

26. Egede LE, Williams JS and. The Association Between Multimorbidity and Quality of Life, Health Status and Functional Disability. The American Journal of the Medical Sciences. 2016; 352: 45–52. https://doi.org/10.1016/j.amjms.2016.03.004

27. Anderson Roger T., Sorlie Paul, Backlund Eric, Johnson Norman, Kaplan George A. Mortality Effects of Community Socioeconomic Status. Epidemiology. 1997; 8: 42–47. https://doi.org/10.1097/00001648-199701000-00007

28. Cohen S, Janicki-Deverts D, Chen E, Matthews KA. Childhood socioeconomic status and adult health. Annals of the New York Academy of Sciences. 2010; 1186: 37–55. https://doi.org/10.1111/j.1749-6632.2009.05334.x

29. Tetzlaff J, Epping J, Sperlich S, Eberhard S, Stahmeyer JT, Geyer S. Widening inequalities in multimorbidity? Time trends among the working population between 2005 and 2015 based on German health insurance data. International journal for equity in health. 2018; 17: 103. https://doi.org/10.1186/s12939-018-0815-z

30. Rodríguez López S, Colantonio SE, Celton DE. Socioeconomic Inequalities in Self-Reported Health and Physical Functioning in Argentina: Findings From The National Survey on Quality of Life Of Older Adults 2012 (Encaviam). Journal of biosocial science. 2017; 49: 597–610. https://doi.org/10.1017/S0021932016000651

31. Báehler C, Huber CA, Brüngger B, Reich O. Multimorbidity, health care utilization and costs in an elderly community-dwelling population: a claims data based observational study. BMC health services research. 2015; 15: 23. https://doi.org/10.1186/s12913-015-0698-2

32. Wang L, Si L, Cocker F, et al. A Systematic Review of Cost-of-Illness Studies of Multimorbidity. Appl Health Econ Health Policy. 2018; 16: 15–29. https://doi.org/10.1007/s40258-017-0346-6

33. Statistiek, Centraal Bureau voor de. Medicijntab: Geneesmiddelen op ATC-code (4). https://www.cbs.nl/nl-nl/onzediensten/maatwerk-en-microdata/microdata-zelf-onderzoek-done/microdatabestanden/medicijntab-geneesmiddelen-op-atc-code-4-

34. WHO Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC classification and DDD assignment. 2019.

35. Huber CA, Szucs TD, Rapold R, Reich O. Identifying patients with chronic conditions using pharmacy data in Switzerland: an updated mapping approach to the classification of medications. BMC public health. 2013; 13: 1030. https://doi.org/10.1186/1471-2458-13-1030

36. Lamers LM, van Vliet RCJA. The Pharmacy-based Cost Group model: validating and adjusting the classification of medications for chronic conditions to the Dutch situation. Health policy. 2004; 68: 113–121. https://doi.org/10.1016/j.healthpol.2003.09.001

37. World HO. Multimorbidity. Geneva: World Health Organization; 2016.

38. Chini F, Pezzotti P, Orzella L, Borgia P, Guastatici G. Can we use the pharmacy data to estimate the prevalence of chronic conditions? a comparison of multiple data sources. BMC public health. 2011; 11: 688. https://doi.org/10.1186/1471-2458-11-688

39. Cortaredona S, Ventelou B. The extra cost of comorbidity: multiple illnesses and the economic burden of non-communicable diseases. BMC Medicine. 2017; 15. https://doi.org/10.1186/s12916-017-0978-2
40. Statistiek, Centraal Bureau voor de. Gbapersoontab: Persoonskenmerken van personen in de BRP. https://www.cbs.nl/nl-nl/onze-diensten/maatwerk-en-microdata/microdata-zelf-onderzoek-goed/microdatabestanden/gbapersoontab-persoonskenmerken-van-persen-in-de-brp.

41. Netherlands Statistics. StatLine—Population dynamics. https://opendata.cbs.nl/statline/#/CBS/en/dataset/83474ENG/table?ts=1570468943729.

42. Statistiek, Centraal Bureau voor de. Gecon: Gezondheidsenquete 2017. https://www.cbs.nl/nl-nl/onze-diensten/maatwerk-en-microdata/microdata-zelf-onderzoek-goed/microdatabestanden/gecon-gezondheidsenquete-2017.

43. Ferretti-Rebustini Renata Eloah, Balbinotti MAA, Jacob-Filho W, Rebustini F, Suemoto CK, Pasqualucci CAG, et al. Validity of the Katz Index to assess activities of daily living by informants in neuropathological studies. Revista da Escola de Enfermagem da USP. 2015; 49: 944–950. https://doi.org/10.1590/ S0080-62342015000600010

44. Arik G, Varan HD, Yavuz BB, Karabulut E, Kara O, Kilic MK, et al. Validation of Katz index of independence in activities of daily living in Turkish older adults. Archives of Gerontology and Geriatrics. 2015; 61: 344–350. https://doi-org.eidm.oclc.org/10.1016/j.archger.2015.08.019.

45. Katz S, Ford AB, Moskowitz RW, Jackson BA, Jaffe MW. Studies of Illness in the Aged: The Index of ADL: A Standardized Measure of Biological and Psychosocial Function. JAMA. 1963; 185: 914–919. https://doi.org/10.1001/jama.1963.03600120024016

46. Wade DT, Collin C. The Barthel ADL Index: A standard measure of physical disability? Disability & Rehabilitation. 1988; 10: 64–67. https://doi.org/10.3109/096382888096144105

47. Caliendo M, Cappellari L. Fixed-Effects and Related Estimators for Correlated Random-Coefficient and Treatment-Effect Panel Data Models. The Review of Economics and Statistics. 2005; 87: 385–390.

48. Manning WG, Mullahy J. Estimating log models: to transform or not to transform? Journal of Health Economics. 2001; 20: 461–494. https://doi.org/10.1016/S0167-6296(01)00868-8

49. Wooldridge JM. Fixed-Effects and Related Estimators for Correlated Random-Coefficient and Treatment-Effect Panel Data Models. The Review of Economics and Statistics. 2005; 87: 385–390.

50. Fortin Martin, Stewart M, Poitras Marie-Eve, Almirall Jose ´ , Maddocks H. A Systematic Review of Prevalence Studies on Multimorbidity: Toward a More Uniform Methodology. Annals of Family Medicine. 2012; 10: 142–151. https://doi.org/10.1370/afm.1337

51. Boeckxstaens P, Vaes B, Legrand D, Dalfour O, De Sutter A, Degryse J. The relationship of multimorbidity with disability and frailty in the oldest patients: A cross-sectional analysis of three measures of multimorbidity in the BELFRAIL cohort. European Journal of General Practice. 2015; 21: 39–44. https://doi.org/10.1016/j.ejim.2015.02.006

52. van Oostrom SH, Picavet HSJ, de Bruin SR, Stirbu I, Korevaar JC, Schellevis FG, et al. Multimorbidity of chronic diseases and health care utilization in general practice. BMC Family Practice. 2014; 15: 61. https://doi.org/10.1186/1471-2296-15-61.

53. Williams JS, Egede LE. The Association Between Multimorbidity and Quality of Life, Health Status and Functional Disability. The American Journal of the Medical Sciences. 2016; 352: 45–52. https://doi.org/10.1016/j.amjms.2016.03.004

54. van Oostrom SH, Picavet HSJ, de Bruin SR, Stirbu I, Korevaar JC, Schellevis FG, et al. Multimorbidity of chronic diseases and health care utilization in general practice. BMC Family Practice. 2014; 15: 61. https://doi.org/10.1186/1471-2296-15-61.

55. Statistiek, Centraal Bureau voor de. Wegening Gezondheidsenqueste 2014. https://www.cbs.nl/nl-nl/achtergrond/2014/18/wegening-gezondheidsenquete-2014.
62. Netherlands Statistics. StatLine—Healthcare expenditure; providers of care and financing source, 1998–2016. https://opendata.cbs.nl/statline/#/CBS/nl/dataset/83039NED/table?fromstatweb.

63. Flanders WD, Lin L, Pirkle JL, Caudill SP. Assessing the Direction of Causality in Cross-sectional Studies. Am J Epidemiol. 1992; 135: 926–935. https://doi.org/10.1093/oxfordjournals.aje.a116388

64. Allison PD. Causal inference with panel data. 2005.

65. Wade DT, Collin C. The Barthel ADL Index: A standard measure of physical disability? International Disability Studies. 1988; 10: 64–67. https://doi.org/10.3109/09638288809164105